PubMed Health⌕ Search

PubMed · 16729824

Electron bubbles in helium clusters. II. Probing superfluidity.

Abstract

In this paper we present calculations of electron tunneling times from the ground electronic state of excess electron bubbles in ((4)He)(N) clusters (N=6500-10(7), cluster radius R=41.5-478 A), where the equilibrium bubble radius varies in the range R(b)=13.5-17.0 A. For the bubble center located at a radial distance d from the cluster surface, the tunneling transition probability was expressed as A(0)phi(d,R)exp(-betad), where beta approximately 1 A(-1) is the exponential parameter, A(0) is the preexponential factor for the bubble located at the cluster center, and phi(d,R) is a correction factor which accounts for cluster curvature effects. Electron tunneling dynamics is grossly affected by the distinct mode of motion of the electron bubble in the image potential within the cluster, which is dissipative (i.e., tau(D) >tau(0)) in superfluid ((4)He)(N) clusters, where tau(D) is the bubble motional damping time (tau(D) approximately 4 x 10(-12) s for normal fluid clusters and tau(D) approximately 10 s for superfluid clusters), while tau(0) approximately 10(-9)-10(-10) s is the bubble oscillatory time. Exceedingly long tunneling lifetimes, which cannot be experimentally observed, are manifested from bubbles damped to the center of the normal fluid cluster, while for superfluid clusters electron tunneling occurs from bubbles located in the vicinity of the initial distance d near the cluster boundary. Model calculations of the cluster size dependence of the electron tunneling time (for a fixed value of d=38-39 A), with lifetimes increasing in the range of 10(-3)-0.3 s for N=10(4)-10(7), account well for the experimental data [M. Farnik and J. P. Toennies, J. Chem. Phys. 118, 4176 (2003)], manifesting cluster curvature effects on electron tunneling dynamics. The minimal cluster size for the dynamic stability of the bubble was estimated to be N=3800, which represents the threshold cluster size for which the excess electron bubble in ((4)He)(N) (-) clusters is amenable to experimental observation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Michael Rosenblit, Joshua Jortner. 2006-05-21. Electron bubbles in helium clusters. II. Probing superfluidity.. https://doi.org/10.1063/1.2192782

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗